1. Advances in Vasodilatory Shock:

2. Objectives

3. Defining Shock

4. Classification of Shock/Various Causes

5. Causes of Vasodilatory Shock

6. Final Common Pathway

7. What Happens in VS?

8. Hemodynamics in VS

9. Systems Involved In Restoring Effective Blood Pressure

10. Goals of Treatment For VS

11. Surviving Sepsis Campaign: Initial Resuscitation

12. Blood Lactate as a Predictor of Survival

13. Dynamic Fluid Assessment in Goal-Directed Therapy

14. Surviving Sepsis Campaign: Fluid Therapy

15. SAFE Trial: Albumin vs Saline Resuscitation

16. ALBIOS: Albumin Replacement in Patients With Severe Sepsis/Septic Shock

17. Gelatin vs Crystalloids and Albumin in Patients With Hypovolemia

18. Surviving Sepsis Campaign: Vasoactive Medications

19. Brief History of Vasopressors

20. Dopamine vs Norepinephrine for the Treatment of Critically Ill

21. Dopamine vs Norepinephrine for the Treatment of Septic Shock

22. Epinephrine vs Norepinephrine for the Treatment of Critically Ill

23. Vasopressin vs Norepinephrine for the Treatment of Septic Shock

24. Vasopressin vs Terlipressin for the Treatment of Vasodilatory Shock

25. Refractory Vasodilatory Shock and Angiotensin II

26. Angiotensin II Trials

27. ATHOS-3: Primary Outcome

28. ATHOS-3: Additional Endpoints

29. Angiotensin II: Current Status

30. V1a Agonist in Patients With Septic Shock

31. Still Evolving…

32. Take Home Points

33. Abbreviations

34. Abbreviations (cont)

35. Abbreviations (cont)

36. Abbreviations (cont)